IN2015DN04172A - - Google Patents
Info
- Publication number
- IN2015DN04172A IN2015DN04172A IN4172DEN2015A IN2015DN04172A IN 2015DN04172 A IN2015DN04172 A IN 2015DN04172A IN 4172DEN2015 A IN4172DEN2015 A IN 4172DEN2015A IN 2015DN04172 A IN2015DN04172 A IN 2015DN04172A
- Authority
- IN
- India
- Prior art keywords
- lateral sclerosis
- amyotrophic lateral
- individual
- therapeutic agent
- ghs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Cell Biology (AREA)
- Marine Sciences & Fisheries (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012234300 | 2012-10-24 | ||
| PCT/JP2013/078743 WO2014065341A1 (ja) | 2012-10-24 | 2013-10-23 | 筋萎縮性側索硬化症治療剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN04172A true IN2015DN04172A (enExample) | 2015-10-16 |
Family
ID=50544716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN4172DEN2015 IN2015DN04172A (enExample) | 2012-10-24 | 2013-10-23 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20150265680A1 (enExample) |
| EP (1) | EP2913063B1 (enExample) |
| JP (1) | JP6262661B2 (enExample) |
| KR (3) | KR102499918B1 (enExample) |
| CN (2) | CN110354265A (enExample) |
| AU (1) | AU2013335678B9 (enExample) |
| BR (1) | BR112015009107A2 (enExample) |
| CA (1) | CA2889499C (enExample) |
| IN (1) | IN2015DN04172A (enExample) |
| RU (1) | RU2655811C2 (enExample) |
| WO (1) | WO2014065341A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10092621B2 (en) | 2014-11-12 | 2018-10-09 | Lyric Pharmaceuticals Inc. | Treatment of enteral feeding intolerance |
| WO2017083882A1 (en) * | 2015-11-11 | 2017-05-18 | Lyric Pharmaceuticals Inc. | Treatment of enteral feeding intolerance and other conditions using ulimorelin analogs |
| KR20210102294A (ko) | 2018-12-06 | 2021-08-19 | 바이오젠 엠에이 인코포레이티드 | 근위축성 측삭 경화증에서 치료요법적 중재를 안내하기 위한 신경필라멘트 단백질 |
| US11969416B1 (en) * | 2022-11-03 | 2024-04-30 | Lumos Pharma, Inc. | Compactable oral formulations of ibutamoren |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5668254A (en) | 1990-05-11 | 1997-09-16 | Romano Deghenghi | D-2-alkyl-tryptophan and peptides containing same |
| US5663146A (en) | 1991-08-22 | 1997-09-02 | Administrators Of The Tulane Educational Fund | Polypeptide analogues having growth hormone releasing activity |
| US5578593A (en) | 1992-12-11 | 1996-11-26 | Merck & Co., Inc. | Spiro piperidines and homologs promote release of growth hormone |
| TW432073B (en) | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| JP4445133B2 (ja) | 1998-08-20 | 2010-04-07 | 大日本住友製薬株式会社 | オキシインドール誘導体 |
| CN100506844C (zh) * | 1999-07-23 | 2009-07-01 | 寒川贤治 | 新的肽 |
| UA73530C2 (uk) | 1999-11-10 | 2005-08-15 | Ново Нордіск А/С | Сполука з властивостями вивільнювати гормон росту |
| US6849597B2 (en) * | 1999-12-28 | 2005-02-01 | Kaken Pharmaceutical Co., Ltd. | Neuroprotective drug |
| ES2292900T3 (es) | 2000-06-13 | 2008-03-16 | Aeterna Zentaris Gmbh | Secretagogos de la hormona del crecimiento. |
| IL162780A0 (en) | 2002-04-11 | 2005-11-20 | Kenji Kangawa | Method for producing modified peptide |
| US7476653B2 (en) | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
| JP2005239712A (ja) | 2004-01-30 | 2005-09-08 | Kaken Pharmaceut Co Ltd | 神経突起伸展剤 |
| WO2006079077A2 (en) * | 2005-01-20 | 2006-07-27 | Acadia Pharmaceuticals Inc. | Use of diltiazem or analogs thereof as modulators of ghrelin receptor |
| US7829589B2 (en) | 2005-06-10 | 2010-11-09 | Elixir Pharmaceuticals, Inc. | Sulfonamide compounds and uses thereof |
| CA2625341A1 (en) * | 2005-10-18 | 2007-04-26 | Ono Pharmaceutical Co., Ltd. | Pharmaceutical for protection of motor nerve in patient with amyotrophic lateral sclerosis |
| CN101460621B (zh) | 2006-06-07 | 2016-01-27 | 建新公司 | 肌萎缩性侧索硬化和其他脊髓失调症的基因治疗 |
| JP2008127377A (ja) | 2006-11-24 | 2008-06-05 | Jichi Medical Univ | Ｇｈｓ−ｒ作動薬を含有してなるメタボリックシンドローム又は高血圧症の予防・治療剤。 |
| KR100946084B1 (ko) | 2008-03-27 | 2010-03-10 | 주식회사 하이닉스반도체 | 반도체 소자의 수직형 트랜지스터 및 그 형성방법 |
| AU2009231394B2 (en) * | 2008-04-03 | 2013-09-05 | F. Hoffmann-La Roche Ag | Use of PEGylated IGF-I variants for the treatment of neuromuscular disorders |
-
2013
- 2013-10-23 KR KR1020227012378A patent/KR102499918B1/ko active Active
- 2013-10-23 KR KR1020157010085A patent/KR20150070180A/ko not_active Ceased
- 2013-10-23 CN CN201910808882.7A patent/CN110354265A/zh active Pending
- 2013-10-23 BR BR112015009107A patent/BR112015009107A2/pt not_active Application Discontinuation
- 2013-10-23 KR KR1020207026038A patent/KR20200108494A/ko not_active Withdrawn
- 2013-10-23 AU AU2013335678A patent/AU2013335678B9/en active Active
- 2013-10-23 CA CA2889499A patent/CA2889499C/en active Active
- 2013-10-23 EP EP13848825.9A patent/EP2913063B1/en active Active
- 2013-10-23 CN CN201380066625.1A patent/CN104853778A/zh active Pending
- 2013-10-23 US US14/437,459 patent/US20150265680A1/en not_active Abandoned
- 2013-10-23 WO PCT/JP2013/078743 patent/WO2014065341A1/ja not_active Ceased
- 2013-10-23 JP JP2014543332A patent/JP6262661B2/ja not_active Expired - Fee Related
- 2013-10-23 RU RU2015119472A patent/RU2655811C2/ru active
- 2013-10-23 IN IN4172DEN2015 patent/IN2015DN04172A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220051418A (ko) | 2022-04-26 |
| CN110354265A (zh) | 2019-10-22 |
| JP6262661B2 (ja) | 2018-01-17 |
| KR20150070180A (ko) | 2015-06-24 |
| BR112015009107A2 (pt) | 2017-11-14 |
| EP2913063B1 (en) | 2019-09-11 |
| RU2015119472A (ru) | 2016-12-20 |
| WO2014065341A1 (ja) | 2014-05-01 |
| CN104853778A (zh) | 2015-08-19 |
| US20150265680A1 (en) | 2015-09-24 |
| RU2655811C2 (ru) | 2018-05-29 |
| HK1214152A1 (en) | 2016-07-22 |
| AU2013335678B9 (en) | 2024-12-12 |
| CA2889499C (en) | 2019-09-10 |
| CA2889499A1 (en) | 2014-05-01 |
| EP2913063A1 (en) | 2015-09-02 |
| KR102499918B1 (ko) | 2023-02-14 |
| JPWO2014065341A1 (ja) | 2016-09-08 |
| KR20200108494A (ko) | 2020-09-18 |
| AU2013335678B2 (en) | 2017-10-26 |
| EP2913063A4 (en) | 2016-07-20 |
| AU2013335678A1 (en) | 2015-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Panlilio et al. | Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction | |
| ZA202108745B (en) | Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof | |
| PH12013501244A1 (en) | A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease | |
| MX2014011353A (es) | Inmunomodulacion de compuestos ciclicos del bucle bc de muerte celular programada (pd1) humana. | |
| PH12014502516B1 (en) | Formulations and methods for vaginal delivery of antiprogestins | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| PH12014500472A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| EA027953B9 (ru) | АЗОТСОДЕРЖАЩИЕ 5-ЧЛЕННЫЕ ГЕТЕРОЦИКЛЫ, ЗАМЕЩЕННЫЕ КАРБОКСАМИДОМ ИЛИ СУЛЬФОНАМИДОМ, В КАЧЕСТВЕ МОДУЛЯТОРОВ ДЛЯ ЯДЕРНОГО ОРФАНОВОГО РЕЦЕПТОРА RORγ | |
| PH12012501480A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| MX341482B (es) | Antagonistas del receptor ep4 y su uso en el tratamiento de enfermedades mediadas por la il-23. | |
| PH12014500239A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| WO2011157416A3 (de) | Transdermale verabreichung von memantin | |
| PH12014500371A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| IN2014DN05869A (enExample) | ||
| HK1223825A1 (zh) | 包含阿曲生坦的稳定化药物剂型 | |
| HK1203394A1 (en) | Ghrelin receptor agonists for the treatment of achlorhydria | |
| MX2016006657A (es) | Antagonistas de gastrina (por ejemplo, yf476, netazepido) para el tratamiento y prevencion de osteoporosis. | |
| SG10201809506TA (en) | Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | |
| AU2018279669A8 (en) | Carboxylic acid derivative as at AT2R receptor antagonist | |
| MY198069A (en) | Method for preventing or treating autism spectrum disorders by benzoic acid salt | |
| MX337593B (es) | Gemcabeno y derivados para tratar la pancreatitis. | |
| MX2014014813A (es) | Uso de agonistas o antagonistas inversos para el receptor de grelina para tratar trastornos del sueño. | |
| PH12019502122A1 (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
| EA201300722A1 (ru) | Применение агониста каппа-опиоидных рецепторов периферического действия ici 204,448 для приготовления средств для лечения никотиновой зависимости | |
| WO2016193456A3 (en) | Opioid receptor antagonist for use in treating patients with severe constipation |